In this round up of updates and resources, you’ll find a read-out of the May UNAIDS high-level meeting in Geneva, two webinars that spotlight critical issues for vaccines R&D and the potential of broadly neutralizing antibodies, and an upcoming webinar looking at alternatives to long-acting PrEP. Read on and join us!
The HIV Response at UNAIDS High-level Meeting
A high-level meeting in Geneva, held by UNAIDS last month on the margins of the World Health Assembly, brought together advocates and experts through the Global HIV Prevention Coalition to discuss where action is needed most to bolster HIV response and advance global health equity. Read AVAC’s summary of the meeting in our latest P-Values blog.
Vaccines in 2023 and Beyond
AVAC hosted two webinars in commemoration of HIV Vaccine Awareness Day. They offer a snapshot on the state of the field for an HIV vaccine, and explore considerations for the development and delivery of vaccines against future pandemics. Check them out below and read more in our HVAD one-pager!
What’s All the Buzz About: mRNA, manufacturing, vaccines access Local production has emerged as an essential part of the solution for ensuring sustainable and equitable supplies of vaccines in low- and middle-income countries. This webinar explored how local manufacturing and the new mRNA Hub in South Africa could facilitate access and support R&D. Check out the summary and recording.
To bNAb or not to bNAb? The case for broadly neutralizing antibodies AVAC and partners explored the potential role of bNAbs in prevention, the status of research and development, and implications for HIV vaccine research. Check out the summary and recording.
PrEP In Black America Presents Mpox Webinar
PrEP in Black America alongside a panel of experts will discuss the impact of mpox on Black communities, advocacy and mobilization to keep our communities safe, and information on vaccine effectiveness. Tuesday, June 20 at 2:00 PM to 3:30 PM ET. Register here.
PrEP That Booty: The latest on rectal microbicide research for the back door
Most of the coverage of the HIV prevention pipeline is about long-acting, longer-acting, and even longer-acting products that deliver drug throughout the body and require a trained clinician to deliver. However, these attributes are not desirable to many folks, and communities want a range of choices. Learn more about the alternatives at this webinar. Thursday, June 29 at 9:00 AM to 10:30 AM ET. Register here.